Zynex Inc

Zynex, Inc. engages in the design, manufacture, and marketing of medical devices. It sells electrotherapy medical devices used for pain management and rehabilitation. The company also develops a new blood volume monitor for use in hospitals and surgery centers. The company was founded by Thomas Sandgaard in 1996 and is headquartered in Englewood, CO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zynex Inc (ZYXI) achieves record highs in Q4 2022

Zynex Inc (ZYXI) delivered strong financial performance in Q4 2022 and full-year 2022, projecting continued growth in 2023. The company's focus on innovation, regulatory milestones, and operational efficiency positions it well for future success.

Zynex Inc reports robust Q1 earnings, eyes revenue growth

Zynex Inc's Q1 2023 performance reflects strong revenue growth and increased orders, supported by strategic initiatives like stock buybacks.
While facing challenges in scaling the sales force and navigating market dynamics, the company is well-positioned to leverage opportunities for expansion and innovation.
Investors can look forward to continued revenue growth, product development, and potential market expansion as Zynex pursues its growth targets.

Zynex Inc reports record revenue and FDA clearances, reaffirms guidance

Zynex Inc delivered robust financial results in Q2 2023, showcasing consistent profitability and revenue growth across its divisions.
The company's focus on product innovation, FDA clearances, and strategic financial moves underscores its commitment to sustained growth and market leadership.
While facing potential challenges, Zynex Inc remains optimistic about its future outlook, aiming to capitalize on market opportunities and drive continued success.

Zynex reports record revenue and growth outlook, driven by innovation

Zynex Inc (ZYXI) delivered strong financial results in Q3 2023, driven by revenue growth, operational efficiency, and strategic product innovations.
The company's focus on noninvasive pain management solutions and commitment to regulatory milestones underscore its growth potential and market positioning.
While facing challenges such as market competition and operational scalability, Zynex's strengths in financial performance and innovation present opportunities for sustained success.

Zynex Inc (ZYXI) reports record revenue and explores strategic alternatives

Zynex Inc (ZYXI) delivered a strong performance in 2023, marked by record revenue, profitability, and operational achievements, positioning the company for continued growth and success.
While facing challenges related to strategic decision-making and operational execution, Zynex remains well-positioned to capitalize on opportunities for revenue expansion, product innovation, and market leadership.
With a focus on financial stability, product diversification, and strategic growth initiatives, Zynex is poised to navigate challenges, leverage opportunities, and drive value for shareholders in the upcoming year.

Zynex Inc reports revenue growth and FDA clearance success

Zynex Inc (ZYXI) demonstrated solid financial performance in Q1 2024, with revenue growth and positive cash flow.
The company's focus on product innovation, sales expansion, and revenue diversification positions it well for future growth.
While facing challenges such as revenue delays and strategic uncertainties, Zynex remains optimistic about its growth prospects and market opportunities.

Zynex Inc reports strong Q2 performance, eyes $200M revenue target

Zynex Inc delivered a strong Q2 2024 performance with revenue growth, improved sales efficiency, and a positive outlook for the year, targeting $200 million in total revenue.
While facing challenges in revenue diversification and sales force refinement, Zynex maintains a solid gross profit margin and a focus on operational excellence.
The company's Monitoring Solutions division shows promise, with ongoing product milestones and plans for FDA submission, indicating future growth potential and market expansion.
Strategic management of challenges and capitalizing on opportunities position Zynex well for sustained growth and profitability in the evolving healthcare market.

Zynex Inc reports strong Q3 performance and eyes growth opportunities

Zynex Inc's Q3 2024 performance reflects revenue growth, profitability, and strategic reinvestment in the business.
While facing challenges in decision-making and operational efficiency, the company is well-positioned for growth.
Opportunities in expanding sales, launching new products, and exploring partnerships pave the way for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zynex, Inc. engages in the design, manufacture, and marketing of medical devices. It sells electrotherapy medical devices used for pain management and rehabilitation. It also develops a new blood volume monitor for use in hospitals and surgery centers. The company was founded by Thomas Sandgaard in 1996 and is headquartered in Englewood, CO.

ENGLEWOOD, Colo., Oct. 25, 2021 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, announced today that it will host the Company's 2021 third quarter earnings investor webcast on Tuesday, November 2, 2021 at 2:15 p.m.

Zynex Schedules 2021 Third Quarter Earnings Call

The mean of analysts' price targets for Zynex Inc. (ZYXI) points to an 86.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Zynex Inc. (ZYXI) Could Rally 87%: Here's is How to Trade

ENGLEWOOD, Colo., Oct. 13, 2021 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced orders and an increased Adjusted EBITDA estimate for Q3 2021.

Zynex Announces 70% Order Growth and Increases Q3 2021 Adjusted EBITDA Estimate

ENGLEWOOD, Colo., Oct. 8, 2021 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced that Zynex Monitoring Solutions will attend and display the CM-1500 Fluid Management Device at the American Society of Anesthesiologists Annual Conference from October 8 – 12 in San Diego.

Zynex to Display its CM-1500 Fluid Monitoring System at the American Society of Anesthesiologists Annual Conference

Public health officers have been focused on Covid-19 for the last 18 months and all other public health issues have taken a back seat to Covid-19 response efforts. Opioid overdoses have increased during the pandemic.

Zynex Took A Back Seat Due To Covid-19

Zynex, Inc. (ZYXI) CEO Thomas Sandgaard on Q2 2021 Results - Earnings Call Transcript

Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 14.29% and -0.67%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zynex Inc. (ZYXI) Surpasses Q2 Earnings Estimates

Shares of Zynex (NASDAQ:ZYXI) decreased in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 11.11% year over year to $0.08, which beat the estimate of $0.06.

Zynex: Q2 Earnings Insights

ENGLEWOOD, Colo., July 29, 2021 /PRNewswire/ -- 2021 Second Quarter Revenue increased 61% year over year to $31.0 million Orders increased 247% Net income of $2.8 million; Diluted EPS $0.08 Adjusted EBITDA $4.8 million Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today reported financial results for its second quarter ended June 30, 2021.

Zynex Announces 2021 Second Quarter Earnings

ENGLEWOOD, Colo., July 21, 2021 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, announced today that it will host the Company's 2021 second quarter earnings investor webcast on Thursday, July 29, 2021 at 2:15 p.m.

Zynex Schedules 2021 Second Quarter Earnings Call

Zynex Inc. (ZYXI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zynex Inc. (ZYXI) Stock Jumps 6.5%: Will It Continue to Soar?

ENGLEWOOD, Colo., July 15, 2021 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced orders and an increased Adjusted EBITDA estimate for Q2 2021.

Zynex Announces 247% Order Growth and Increases Q2 Adjusted EBITDA Estimate

ENGLEWOOD, Colo., July 13, 2021 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced that effective as of market open on July 14, 2021, its common stock has been approved for uplisting to the Nasdaq Global Select Market® and will continue trading under its current ticker symbol "ZYXI.

Zynex Announces Uplisting to the Nasdaq Global Select Market®

ENGLEWOOD, Colo., July 8, 2021 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced that Dan Moorhead, Chief Financial Officer of Zynex will present virtually at the Ladenburg Thalmann Annual Healthcare Conference on Tuesday, July 13, 2021.

Zynex to Present at the Ladenburg Thalmann Virtual Annual Healthcare Conference

Order growth, and with it revenue growth, will accelerate again after already raking up a 140% growth in Q1.

Zynex: Order Growth, Already At +140%, Is Set To Accelerate

Zynex, Inc. (ZYXI) CEO Thomas Sandgaard on Q1 2021 Results - Earnings Call Transcript

Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 0.00% and 2.10%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zynex Inc. (ZYXI) Reports Q1 Loss, Tops Revenue Estimates

ENGLEWOOD, Colo., April 29, 2021 /PRNewswire/ -- 2021 First Quarter Revenue increased 58% year over year to $24.1 million Orders increased 140% Net loss of $0.7 million; GAAP loss per share $0.02 Adjusted EBITDA loss $0.4 million Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today reported financial results for its first quarter ended March 31, 2021.

Zynex Announces 2021 First Quarter Earnings

ENGLEWOOD, Colo., April 20, 2021 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics today announced that it has hired Donald Gregg as the Vice President of Sales and Operations of its Monitoring Solutions Division.

Zynex Appoints Donald Gregg as Vice President of Sales and Operations of Monitoring Solutions Division

ENGLEWOOD, Colo., April 19, 2021 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, announced today that it will host the Company's 2021 first quarter earnings investor webcast on Thursday, April 29, 2021 at 2:15 p.m.

Zynex Schedules 2021 First Quarter Earnings Call

ENGLEWOOD, Colo., April 12, 2021 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced orders for Q1 2021.

Zynex Announces 140% Year over Year Order Growth in Q1-2021

ENGLEWOOD, Colo., April 9, 2021 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced that it is moving to a new corporate headquarters to accommodate its' continued growth.

Zynex Growth Leads to New Corporate Headquarters

ENGLEWOOD, Colo., March 30, 2021 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics today announced the Denver Business Journal has recognized Zynex as the sixth largest Biotechnology/Bioscience public company in Colorado based on number of companywide employees as of November 1, 2020.

Zynex Recognized as the Sixth Largest Biotechnology/Bioscience Company in Colorado

Airbnb

Editas Medicine

CenterPoint Energy

Agios Pharmaceuticals

Denali Therapeutics

PetroChina Company Ltd.

LendingTree

Voyager Therapeutics

With the trading day more than halfway over, the broad markets recovered slightly from Thursday's downturn, with the exception of the Dow Jones industrial average.

Airbnb, Centerpoint, Editas and More Friday Afternoon Analyst Calls

Investors are reacting negatively to the company's Q4 results and Q1 outlook.

News for Zynex Inc Stock (ZYXI)